Form 4: Assertio Holdings CEO Brendan O'Grady Acquires Stock Options and Restricted Stock Units

Assertio Holdings CEO Brendan O'Grady was granted stock options and restricted stock units on May 31, 2024.

Summary

• On May 31, 2024, Brendan P. O'Grady, CEO of Assertio Holdings, Inc., was granted 500,000 restricted stock units and 1,800,000 stock options.
• The exercise price for the stock options is $0.99.
• One-third of the restricted stock units and stock options are scheduled to vest annually over the first three years from the grant date, contingent upon continued employment.
• The restricted stock units represent a contingent right to receive one share of Assertio Holdings' common stock.
• The stock options expire on May 31, 2034.
• The reporting person did not pay any consideration for the derivative securities.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The grant of stock options and restricted stock units is a standard practice that aligns management's interests with shareholders. The vesting schedule encourages long-term commitment.

Positives

• The grant of stock options and restricted stock units aligns the CEO's interests with those of the shareholders.
• Vesting is tied to continued employment, incentivizing the CEO to remain with the company.

Future Outlook

The vesting schedule suggests a three-year commitment from the CEO, aligning his interests with the long-term performance of the company.

Industry Context

Grants of stock options and restricted stock units are common practices in the pharmaceutical industry to incentivize and retain key executives.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the pharmaceutical industry, often benchmarked against peer companies of similar size and market capitalization.
• Companies like Teva Pharmaceutical Industries Ltd. and Mylan N.V. (now Viatris) have historically used similar equity-based compensation to align executive incentives with shareholder value.
• The vesting schedule of one-third annually over three years is also a common practice, ensuring continued service and commitment from the executive.

Stakeholder Impact

• Shareholders may view the grant positively as it aligns the CEO's interests with the company's performance.
• Employees may see this as a sign of confidence in the company's future.

Key Dates